Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Accelerating sustainability in Indian pharma industry
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Subscribe To Our Newsletter & Stay Updated
